Upgrade Alert for AstraZeneca (AZN)
AstraZeneca (NYSE:AZN) was upgraded from Hold to Buy at Jefferies today. The stock closed yesterday at $33.24 on volume of 3.6 million shares, below average daily volume of 3.7 million.
Over the past year, AstraZeneca has traded in a range of $26.97 to $70.67 and closed yesterday at $33.24, 23% above that low. Over the past week, the 200-day moving average (MA) has gone down 2.4% while the 50-day MA has declined 0.2%.
Potential upside of 29.5% exists for AstraZeneca, based on a current level of $33.24 and analysts' average consensus price target of $43.05. AstraZeneca shares have support at the 200-day moving average (MA) of $32.02 and additional support at the 50-day MA of $29.04.
AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
SmarTrend is tracking the current trend status for AstraZeneca and will alert subscribers who have AZN in their portfolio or watchlist when shares have changed trend direction.
Keywords: analyst upgrades/downgrades AstraZeneca